Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.
Immunotherapy
; 13(6): 509-525, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33626932
ABSTRACT
In recent years, immune-checkpoint inhibitors (ICIs) have represented one of the major breakthroughs in advanced non-small cell lung cancer treatment scenario. However, enrollment in registering clinical trials is usually restricted, since frail patients (i.e., elderly, individuals with poor performance status and/or active brain metastases), as well as patients with chronic infections or who take concurrent medications, such as steroids, are routinely excluded. Thus, safety and efficacy of ICIs for these subgroups have not been adequately assessed in clinical trials, although these populations often occur in clinical practice. We reviewed the available data regarding the use of ICIs in these 'special' populations, including a focus on the issues raised by the administration of immunotherapy in lung cancer patients infected with Sars-Cov-2.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Populações Vulneráveis
/
Inibidores de Checkpoint Imunológico
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article